GenVec Ditches Liquidation Plan For Novartis Partnership

Law360, New York (September 4, 2013, 4:18 PM EDT) -- Flagging biotech firm GenVec Inc. has scrapped plans to dissolve and liquidate assets amid encouraging prospects for a program to develop new hearing loss treatments in partnership with Novartis AG and successful efforts to trim costs, its board said Wednesday.

As part of its new operating strategy, an about-face from the liquidation plan unveiled in late May, the Maryland company also announced a leadership shakeup. GenVec President and CEO Cynthia Collins resigned and gave up her board seat, making way for Douglas Swirsky, the company's senior...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.